Clinical Trial

Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2020-08-07; most recent amendment 2026-06-29.
Status change: Recruiting → Active, Not Recruiting 2025-06-30
Trial Details
NCT Number NCT04505436
Lead Sponsor Hanmi Pharmaceutical Company Limited
Conditions NASH - Nonalcoholic Steatohepatitis
Enrollment 215 participants
Start Date 2020-07-31
Primary Completion 2026-06-27 (estimated)
Study Completion 2026-07-27 (estimated)
Updated on ClinicalTrials.gov 2026-06-30